TuisLSTA • NASDAQ
add
Lisata Therapeutics Inc
Vorige sluiting
$2,06
Dagwisseling
$2,00 - $2,09
Jaarwisseling
$1,81 - $4,20
Markkapitalisasie
17,99 m USD
Gemiddelde volume
101,53 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 4,41 m | -17,28% |
Netto inkomste | -4,25 m | 13,81% |
Netto winsgrens | — | — |
Wins per aandeel | -0,49 | 16,95% |
EBITDA | -4,37 m | 17,45% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 19,00 m | -47,02% |
Totale bates | 21,76 m | -43,04% |
Totale aanspreeklikheid | 4,64 m | -2,58% |
Totale ekwiteit | 17,12 m | — |
Uitstaande aandele | 8,82 m | — |
Prys om te bespreek | 1,04 | — |
Opbrengs op bates | -47,04% | — |
Opbrengs op kapitaal | -58,17% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -4,25 m | 13,81% |
Kontant van bedrywe | -3,34 m | -32,72% |
Kontant van beleggings | 5,15 m | 181,68% |
Kontant van finansiering | 353,00 k | — |
Netto kontantverandering | 2,16 m | 124,62% |
Beskikbare kontantvloei | -1,84 m | -115,02% |
Meer oor
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Gestig
1980
Webwerf
Werknemers
26
